PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
To observe the safety, tolerability and clinical effects of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide in Relapsed or Refractory NK/T cell Lymphoma.
NK/T Cell Lymphoma
DRUG: PD-1 Antibody, chidamide, lenalidomide and etoposide
Overall Response Rate, The proportion of patients whose tumor volume has reduced to a predetermined value and can maintain the minimum time limit is the sum of complete and partial mitigation., From date of randomization until the date of first date tumor volume has reduced, assessed up to 36 months
Progression-free Survival, The time between the start of randomization and the progression of the tumor (any aspect) or (for any reason) death, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months|Overall Survival, Time from randomization to death for any reason., From date of randomization until date of death from any cause, assessed up to 36 months
This is a prospective, open-label, one-arm, multicenter clinical trial, aimed to evaluate the safety, tolerability, and efficacy of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide in Relapsed or Refractory NK/T cell Lymphoma. A total of 50 patients are planned to be enrolled into the study. The primary end points are objective responder rate (ORR) and progression free survival(PFS) and the secondary end points include overall survival(OS) , and adverse events.